‘Rope Not Dope’ Still Convince Congress On Hemp?
Failing to maintain key non-intoxicating distinction for hemp could cost US market its future. FDA appointment of senior policy advisor for cannabis could change things.
You may also be interested in...
It could take next farm bill, on lawmakers’ 2023 to-do list, to extinguish inferno of disagreement between FDA and regulated industries over lawful use of hemp-based ingredients in supplements as well as food and non-drug topicals. Before 2018 bill de-scheduled hemp, 2014 bill expanded access to hemp for research.
Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.
Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.